Federal “pause” in the management of Johnson & Johnson
The coronavirus vaccine does not seem to compromise public confidence in the vaccination process, a new survey found.
Fifty-three percent of respondents polled after the pause agreed that this was “a prime example of the COVID-19’s rigorous safety surveillance being used to protect Americans” . In contrast, 29% said the suspension was a case study of why the COVID-19 vaccine should be avoided.
Poll done by Frank Luntz poll of 1,000 registered voters April 15 and April 16 for the de Beaumont Foundation, an organization focused on public health.
The survey paused for a week for J&J COVID-19 photographs after they were linked eight severe cases of blood clotting United States, out of 7.4 million people who received an injection last week. Seven out of eight people have experienced extremely rare blood clots is a woman.
Nearly two-thirds (63%) of the survey respondents said that everyone should still try to get Pfizer
vaccine, both two-dose product.
6 out of 10 people report that they view blood clots under close supervision as separate cases and believe vaccines are generally safe.
Brian Castrucci, president and chief executive officer of the de Beaumont Foundation, said in a statement: “The Americans recognize the Johnson & Johnson vaccine suspension – a clear indication of the safety procedures of the We are operating the way they should, ”said Brian Castrucci, president and CEO of the de Beaumont Foundation, in a statement. “Government officials must remain transparent and use clear, consistent language about vaccines.”
That doesn’t mean no damage can be done by the pause. As one expert previously told MarketWatch, the pause could seed deeper suspicion for some.
“These are more troubling for those who are hesitant about vaccines,” said Aaron Glatt, chair of the medical department at Mount Sinai South Nassau in Oceanside, NY
A Center for Disease Control and Prevention advisory committee is scheduled to meet on Friday to discuss what’s next for Johnson & Johnson.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, tell news programs Sunday that he would be “very surprised if we don’t have some form back on Friday.”
On Tuesday, Johnson & Johnson said it would restart vaccine shipments to Europe. The European Pharmaceutical Authority says the benefits outperform Side effects are “very rare”, but added that a warning about the possibility of rare clotting should be included in the vaccine documentation.
No matter how US public health officials decide, a recent poll shows that the J&J shot may be subject to more suspicion on the other side.
In a survey of respondents who voted for the last presidential election, 32% of all voters said they would never get the J&J vaccine. Much of that hesitation came from voters supporting former President Donald Trump, with 44% saying they would never agree to the statement. Eighteen percent of those who voted for President Biden said the same.
Those political divisions emerge in the broader question of vaccine hesitation, where Republicans have tends to be more reluctant.
Last month, Trump said in an interview he would “recommend it to a lot of people who didn’t want it, and a lot of people voted for me frankly.”
The new survey showed melted rejection from Trump supporters: 70% said this month they had received at least one shot or “sure or possibly” would be shot. This figure is up from 59% last month, when the de Beaumont Foundation previously surveyed Trump supporters on the question.
“There are still significant, measurable differences between Republicans and Democrats as they accept the COVID vaccine,” Luntz said in a statement. “The good news is that the partisan gap is decreasing and confidence in vaccines in general is growing.”
Overall, 132.3 million people – nearly 40% of Americans – have received at least one dose of the vaccine as of Tuesday, and 85.3 million have been fully vaccinated, according to CDC data. At the same time, the country has recorded 31.7 million total cases of COVID-19 cases and 567,759 deaths, according to aggregated data of Johns Hopkins University.
“The safety and well-being of the people who use our products are our number one priority,” said Paul Stoffel, J&J’s scientific director, in a statement Tuesday about news about shipments are resumed to the European Union, Norway and Iceland.
“We truly believe in the positive benefits of the easy-to-transport, single-shot COVID-19 vaccine to help protect the health of people everywhere and reach communities in need across the globe. bridge.”